Medinet Co

Medinet Co Operating Cash Flow

The Operating Cash Flow of Medinet Co (2370.T) as of Oct 26, 2026 is -1.41 B JPY. In the previous year, Operating Cash Flow was -1.19 B JPY — a change of 18.44% (lower).

Operating Cash Flow

-1.41 BJPY

YoY

18.44%

Last updated:

Operating Cash Flow of Medinet Co is 2025 -1.41 B JPY. Operating Cash Flow of Medinet Co was 2024 -1.19 B JPY. It decreases by 18.44% lower compared to the previous year.

The Medinet Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-2.50 B JPY
Jan 1, 2019
-917.11 M JPY
Jan 1, 2020
-547.54 M JPY
Jan 1, 2021
-612.08 M JPY
Jan 1, 2022
-1.13 B JPY
Jan 1, 2023
-1.26 B JPY
Jan 1, 2024
-1.19 B JPY
Jan 1, 2025
-1.41 B JPY
The Medinet Co Operating Cash Flow history
YEAROperating Cash FlowYoY
-1.41 BJPY+18.44%
-1.19 BJPY-5.16%
-1.26 BJPY+11.25%
-1.13 BJPY+84.79%
-612.08 MJPY+11.79%
-547.54 MJPY-40.30%
-917.11 MJPY-63.31%
-2.50 BJPY+87.49%
-1.33 BJPY+22.52%
-1.09 BJPY-30.58%
-1.57 BJPY+53.65%
-1.02 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinet Co Stock analysis

What does Medinet Co do? MEDINET Co., Ltd. generates revenue through its Cell Processing Industry segment, which offers comprehensive support services for immune cell therapy, including clinical use from companies, universities, and research institutes, outsourcing cell processing for clinical trials, and operating cell culture processing facilities. The Cellular Medical Products segment focuses on research and development to obtain approval for manufacturing and marketing cellular medical products. The company serves clients in the healthcare sector, particularly entities involved in immune cell therapy and cellular medical product development. The Cell Processing Industry segment provides outsourcing services for cell processing in clinical trials, catering to companies, universities, and research institutes seeking specialized processing capabilities. The Cellular Medical Products segment develops cellular medical products requiring regulatory approval, targeting manufacturers and marketers in the medical field. Both segments operate under MEDINET's expertise in cell processing and medical product development. MEDINET's business model relies on delivering specialized cell processing services and supporting the regulatory approval process for cellular medical products. The company's clients include organizations engaged in immune cell therapy research and development, as well as those seeking to commercialize cellular medical products. The dual-segment approach ensures comprehensive coverage of the cell processing and medical product development lifecycle. Medinet Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinet Co stock

Operating Cash Flow of Medinet Co is -1.41 B JPY in 2025.

Operating Cash Flow of Medinet Co changed from -1.19 B JPY to -1.41 B JPY, representing a 18.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Medinet Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Medinet Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medinet Co

All Key Metrics — Medinet Co